SKYSCRAPER-02, the first randomized study of tiragolumab in ES-SCLC, did not meet co-primary endpoint of PFS, Genentech says

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Genentech announced that the phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA, and the UCLA Fielding School of Public Health, was awarded a $2.5 million grant from the Bristol Myers Squibb Foundation, an independent charitable organization, to spearhead a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login